Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7396 to 7410 of 7707 results

  1. Nivolumab with docetaxel for treating hormone-relapsed advanced prostate cancer after 1 or 2 hormonal therapies [ID4048]

    Discontinued [GID-TA10929]

    Technology appraisal guidance
    Discontinued

  2. Atezolizumab with cabozantinib for treating metastatic non-small-cell lung cancer after platinum-based chemotherapy and 1 PD-L1 checkpoint inhibitor [ID6213]

    Discontinued [GID-TA11204]

    Technology appraisal guidance
    Discontinued

  3. Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]

    Discontinued [GID-TA10848]

    Technology appraisal guidance
    Discontinued

  4. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued [GID-TA10861]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]

    Discontinued [GID-TA10880]

    Technology appraisal guidance
    Discontinued

  6. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725]

    In development [GID-TA11014] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]

    In development [GID-TA11093] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cancer (IPG614)

    This guidance has been updated and replaced by NICE interventional procedures guidance 794.

    Interventional procedures guidance
    Published
    23 May 2018

  10. Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]

    Discontinued [GID-TA10961]

    Technology appraisal guidance
    Discontinued

  11. Teclistamab for treating relapsed or refractory multiple myeloma after 3 or more therapies (terminated appraisal) (TA869)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1015.

    Technology appraisal guidance
    Published
    16 February 2023

  12. Non-invasive skin closure devices for surgical incisions (MT775)

    In development [GID-MT593] Expected publication date: TBC

    Medical technologies guidance
    In development

  13. Stye: antimicrobial prescribing

    Discontinued [GID-NG10167]

    Antimicrobial prescribing guideline
    Discontinued

  14. Skin abscess: antimicrobial prescribing

    Discontinued [GID-NG10163]

    Antimicrobial prescribing guideline
    Discontinued

  15. SILK artery reconstruction device (discontinued)

    Discontinued [GID-MT81]

    Medical technologies guidance
    Discontinued